(S)-(+)-6-氯己烷-2-醇 | 102108-32-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (S)-(+)-6-氯己烷-2-醇
• 英文名称: (S)-(+)-6-chlorohexan-2-ol
• 英文别名: (2S)-6-chlorohexan-2-ol
• CAS: 102108-32-7
• 化学式: C₆H₁₃ClO
• 分子量: 136.622
• InChiKey: LDIPECSHAACCTQ-LURJTMIESA-N

物化性质

• 沸点：
  190.4±23.0 °C(Predicted)
• 密度：
  0.998±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (S)-(+)-6-氯己烷-2-醇 在 sodium hydride 作用下， 反应 3.0h， 以95%的产率得到(S)-(+)-2-甲基四氢吡喃
  参考文献：
  名称：

  Organic synthesis with enzymes. 3. TBADH-catalyzed reduction of chloro ketones. Total synthesis of (+)-(S,S)-(cis-6-methyltetrahydropyran-2-yl)acetic acid: a civet constituent

  摘要：

  DOI：

  10.1021/ja00272a051
• 作为产物：
  描述：

  6-氯-2-己酮 在 mercaptoethyl alcohol 、 Tris-HCl buffer 作用下， 以 水 、 异丙醇 为溶剂， 生成 (S)-(+)-6-氯己烷-2-醇
  参考文献：
  名称：

  Organic synthesis with enzymes. 3. TBADH-catalyzed reduction of chloro ketones. Total synthesis of (+)-(S,S)-(cis-6-methyltetrahydropyran-2-yl)acetic acid: a civet constituent

  摘要：

  DOI：

  10.1021/ja00272a051

文献信息

• Chiral Surfactant-Type Catalyst for Asymmetric Reduction of Aliphatic Ketones in Water
  作者：Jiahong Li、Yuanfu Tang、Qiwei Wang、Xuefeng Li、Linfeng Cun、Xiaomei Zhang、Jin Zhu、Liangchun Li、Jingen Deng

  DOI：10.1021/ja308357y

  日期：2012.11.14

  A novel chiral surfactant-type catalyst is developed. Micelles formed in water by association of the catalysts themselves, and this was confirmed by TEM analyses. Asymmetric transfer hydrogenation of aliphatic ketones catalyzed by the chiral metallomicellar catalyst gave good to excellent conversions and remarkable stereoselectivities (up to 95% ee). Synergistic effects between the metal-catalyzed

  开发了一种新型手性表面活性剂型催化剂。通过催化剂本身的结合在水中形成胶束，这通过 TEM 分析得到证实。由手性金属胶束催化剂催化的脂肪族酮的不对称转移氢化具有良好到优异的转化率和显着的立体选择性（高达 95% ee）。金属催化中心与金属胶束中核心的疏水微环境之间的协同作用导致高对映选择性。
• Substituted xanthine derivatives
  申请人：Tung Roger D.

  公开号：US20090239886A1

  公开（公告）日：2009-09-24

  This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

  本发明涉及新型化合物，即取代黄嘌呤衍生物及其药学上可接受的盐。例如，本发明涉及新型取代黄嘌呤衍生物，它们是戊酰异丙基黄嘌呤的衍生物。本发明还提供了包含本发明中的一种或多种化合物和载体的组合物，以及把所述化合物和组合物用于治疗戊酰异丙基黄嘌呤和相关化合物有益的疾病和病况的方法。
• [EN] SUBSTITUTED XANTHINE DERIVATIVES<br/>[FR] DÉRIVÉS DE XANTHINE SUBSTITUÉS
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2011028835A1

  公开（公告）日：2011-03-10

  This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

  本发明涉及新型化合物，它们是取代黄嘌呤衍生物及其药学上可接受的盐。例如，本发明涉及新型取代黄嘌呤衍生物，它们是戊申酰丙胺的衍生物。本发明还提供了包含本发明化合物之一或多个和载体的组合物以及使用所披露的化合物和组合物治疗戊申酰丙胺和相关化合物有益的疾病和病状的方法。
• SUBSTITUTED XANTHINE DERIVATIVES
  申请人：Tung Roger D.

  公开号：US20110053961A1

  公开（公告）日：2011-03-03

  This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

  本发明涉及一种新型化合物，它们是取代黄嘌呤衍生物及其药学上可接受的盐。例如，本发明涉及一种新型的取代黄嘌呤衍生物，它们是戊酰苄氨基甲基黄嘌呤的衍生物。本发明还提供了包括本发明中的一个或多个化合物和载体的组合物，并且揭示了这些化合物和组合物在治疗戊酰苄氨基甲基黄嘌呤和相关化合物有益的疾病和病症的方法中的应用。
• SUBSTITUED XANTHINE DERIVATIVES
  申请人：Concert Pharmaceuticals Inc.

  公开号：EP3199203A1

  公开（公告）日：2017-08-02

  A pharmaceutical composition comprising: a. an effective amount of a compound of Formula B: or a pharmaceutically acceptable salt thereof; b. a second therapeutic agent selected from insulin or insulin analogues, glucagon-like-peptide-1 (GLP-1) receptor agonists, sulfonylurea agents, biguanide agents, alpha-glucosidase inhibitors, PPAR agonists, meglitinide agents, dipeptidyl-peptidase (DPP) IV inhibitors, phosphodiesterase inhibitors, amylin agonists, CoEnzyme A inhibitors, and antiobesity agents; and c. a pharmaceutically acceptable car.

  一种药物组合物，包括 a. 有效量的式 B 化合物： 或其药学上可接受的盐； b. 第二种治疗剂，选自胰岛素或胰岛素类似物、胰高血糖素样肽-1 (GLP-1) 受体激动剂、磺酰脲类药物、双胍类药物、α-葡萄糖苷酶抑制剂、PPAR 激动剂、甲格列脲类药物、二肽基肽酶 (DPP) IV 抑制剂、磷酸二酯酶抑制剂、淀粉样蛋白激动剂、辅酶 A 抑制剂和抗肥胖药；以及 c. 医药上可接受的载体。